AbbVie Inc
For the period ended Dec 31, 2024. Filed Feb 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 14, 2025
ABBV$293.89+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Income
| years ended December 31 (in millions) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net earnings | $4,286 | $4,873 | $11,845 |
| Foreign currency translation adjustments, net of tax expense (benefit) of $(39) in 2024, $15 in 2023 and $(10) in 2022 | (1,008) | 407 | (943) |
| Net investment hedging activities, net of tax expense (benefit) of $133 in 2024, $(109) in 2023 and $152 in 2022 | 484 | (399) | 555 |
| Pension and post-employment benefits, net of tax expense (benefit) of $206 in 2024, $(6) in 2023 and $272 in 2022 | 824 | (30) | 1,088 |
| Cash flow hedging activities, net of tax expense (benefit) of $16 in 2024, $(19) in 2023 and $5 in 2022 | 80 | (84) | — |
| Other comprehensive income (loss) | $380 | $(106) | $700 |
| Comprehensive income | 4,666 | 4,767 | 12,545 |
| Comprehensive income attributable to noncontrolling interest | 8 | 10 | 9 |
| Comprehensive income attributable to AbbVie Inc. | $4,658 | $4,757 | $12,536 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.